Constellation Pharmaceuticals, Inc. ( CNST) Stock. Should you Buy or Sell? $ 33.99
0.00 (0.00 %)
Constellation Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | CNST |
| Price | $33.99 |
| Beta | 2.580 |
| Volume Avg. | $1.57 M |
| Market Cap | $1.63 B |
| 52 Week Range | $17.0 - $39.3 |
Constellation Pharmaceuticals, Inc. opened the day at $33.99 which is 0.00 % on yesterday's close. Constellation Pharmaceuticals, Inc. has a 52 week high of $39.3 and 52 week low of $17.0, which is a difference of $22.3. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.63 B and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Constellation Pharmaceuticals, Inc. for $1.63 B, it would take 15 years to get your money back. Constellation Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Constellation Pharmaceuticals, Inc. Stock Forecast - Is Constellation Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Neutral | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -11.533 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Constellation Pharmaceuticals, Inc.
| Price Book Value Ratio | 4.309 | Price To Book Ratio | 4.309 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -11.533 |
How liquid is Constellation Pharmaceuticals, Inc.
| Current Ratio | 15.389 |
| Quick Ratio | 15.078 |
Debt
| Debt Ratio | 0.063 | Debt Equity Ratio | 0.067 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about Constellation Pharmaceuticals, Inc.
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.00 per share, net to the seller in cash, without interest and subject to any applicable withholding of taxes. The tender offer expired at one minute after 11:59 p.m.
CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that three posters relating to the MANIFEST clinical trial of pelabresib (CPI-0610) in myelofibrosis (MF) were published online in association with the European Hematology Association (EHA) annual meeting. The data in these posters are based on a data cutoff of September 29, 2020 from the MANIFEST Phase 2 clinical trial and reflect an analysis of pelabresib clinical and translational activity.
NEW YORK, June 4, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Constellation Pharmaceuticals, Inc. ("CNST" or the "Company") ( CNST ) relating to its proposed acquisition by MorphoSys AG (MOR). Under the terms of the agreement, CNST shareholders will receive $34.00 in cash per share they own.
The small drugmaker is being acquired by MorphoSys.
NEW YORK, June 2, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Constellation Pharmaceuticals, Inc. ("Constellation" or the "Company") (NASDAQ: CNST) in connection with the proposed acquisition of the Company by MorphoSys AG ("MorphoSys") (FSE: MOR; NASDAQ: MOR). The transaction is structured as an all-cash tender offer pursuant to which the Company's shareholders will receive $34.00 for each share of Constellation common stock that they hold.
About Constellation Pharmaceuticals, Inc.
Description :
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
